Spyre Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
SYRE$109.00+4.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
SPYRE THERAPEUTICS, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
|---|---|
| Audited Consolidated Financial Statements | |
| Report of Independent Registered Public Accounting Firm (ID 238 PricewaterhouseCoopers LLP) | 90 |
| Consolidated Balance Sheets | 92 |
| Consolidated Statements of Operations | 93 |
| Consolidated Statements of Comprehensive Loss | 94 |
| Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity | 95 |
| Consolidated Statements of Cash Flows | 96 |
| Notes to Consolidated Financial Statements | 97 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.